<DOC>
	<DOC>NCT01789320</DOC>
	<brief_summary>This study is designed to determine the safety and tolerability of a single microinjection of triamcinolone acetonide (TRIESENCE®) into the suprachoroidal space (SCS) of patients who have non-infectious uveitis.</brief_summary>
	<brief_title>Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis</brief_title>
	<detailed_description>This is a Phase 1/2, open-label study designed to evaluate the safety, tolerability and procedure of a microneedle injection of triamcinolone acetonide (TA) into the SCS. The subjects enrolled in this study will be chosen from subjects with non-infectious intermediate, posterior and pan-uveitis. The injection will only be administered to a single eye via the Clearside Biomedical proprietary microneedle into the SCS. The dose of TA to be injected is 4 mg of currently approved TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL). The study design includes 10 clinic visits over 27 weeks. Subjects will be followed for 26 weeks following treatment with TRIESENCE®.</detailed_description>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis, Posterior</mesh_term>
	<mesh_term>Uveitis, Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>diagnosis of noninfectious intermediate, posterior or panuveitis any ocular trauma within the past 6 months in the study eye any injection of intraocular corticosteroids or steroid implant or the Ozurdex® implant in the 6 months prior to the study treatment, or any prior use of Retisert™ in the study eye any uncontrolled systemic disease that would preclude participation in the study or put the subject at risk due to study treatment or procedures have a known HIV infection or other immunodeficiency disease for which corticosteroid therapy would be contraindicated are monocular have ocular hypertension history of any intraocular surgery in the study eye presence of an anterior staphyloma in the study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>uveitis</keyword>
	<keyword>intermediate uveitis</keyword>
	<keyword>posterior uveitis</keyword>
	<keyword>panuveitis</keyword>
	<keyword>noninfectious uveitis</keyword>
	<keyword>microneedle</keyword>
	<keyword>suprachoroidal space</keyword>
	<keyword>SCS</keyword>
	<keyword>inflammation</keyword>
	<keyword>ocular inflammatory conditions</keyword>
	<keyword>triamcinolone acetonide</keyword>
	<keyword>TA</keyword>
	<keyword>Triesence</keyword>
	<keyword>injection</keyword>
	<keyword>IVT</keyword>
	<keyword>intravitreal</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>sympathetic ophthalmia</keyword>
	<keyword>temporal arteritis</keyword>
	<keyword>vitreous haze</keyword>
</DOC>